Your browser doesn't support javascript.
loading
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Datoo, Mehreen S; Natama, Magloire H; Somé, Athanase; Traoré, Ousmane; Rouamba, Toussaint; Bellamy, Duncan; Yameogo, Prisca; Valia, Daniel; Tegneri, Moubarak; Ouedraogo, Florence; Soma, Rachidatou; Sawadogo, Seydou; Sorgho, Faizatou; Derra, Karim; Rouamba, Eli; Orindi, Benedict; Ramos Lopez, Fernando; Flaxman, Amy; Cappuccini, Federica; Kailath, Reshma; Elias, Sean; Mukhopadhyay, Ekta; Noe, Andres; Cairns, Matthew; Lawrie, Alison; Roberts, Rachel; Valéa, Innocent; Sorgho, Hermann; Williams, Nicola; Glenn, Gregory; Fries, Louis; Reimer, Jenny; Ewer, Katie J; Shaligram, Umesh; Hill, Adrian V S; Tinto, Halidou.
  • Datoo MS; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Natama MH; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Somé A; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Traoré O; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Rouamba T; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Bellamy D; The Jenner Institute Laboratories, University of Oxford, UK.
  • Yameogo P; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Valia D; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Tegneri M; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Ouedraogo F; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Soma R; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Sawadogo S; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Sorgho F; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Derra K; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Rouamba E; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Orindi B; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Ramos Lopez F; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Flaxman A; The Jenner Institute Laboratories, University of Oxford, UK.
  • Cappuccini F; The Jenner Institute Laboratories, University of Oxford, UK.
  • Kailath R; The Jenner Institute Laboratories, University of Oxford, UK.
  • Elias S; The Jenner Institute Laboratories, University of Oxford, UK.
  • Mukhopadhyay E; The Jenner Institute Laboratories, University of Oxford, UK.
  • Noe A; The Jenner Institute Laboratories, University of Oxford, UK.
  • Cairns M; London School of Hygiene & Tropical Medicine, London, UK.
  • Lawrie A; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Roberts R; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Valéa I; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Sorgho H; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
  • Williams N; Department of Primary Care, University of Oxford, UK.
  • Glenn G; Novavax, Gaithersburg, MD, USA.
  • Fries L; Novavax, Gaithersburg, MD, USA.
  • Reimer J; Novavax, Uppsala, Sweden.
  • Ewer KJ; The Jenner Institute Laboratories, University of Oxford, UK.
  • Shaligram U; Serum Institute of India, Pune, India.
  • Hill AVS; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; The Jenner Institute Laboratories, University of Oxford, UK. Electronic address: adrian.hill@ndm.ox.ac.uk.
  • Tinto H; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso. Electronic address: tintoh@crun.bf.
Lancet ; 397(10287): 1809-1818, 2021 05 15.
Article en En | MEDLINE | ID: mdl-33964223
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Antiprotozoarios / Proteínas Protozoarias / Vacunas contra la Malaria / Vacunas de Partículas Similares a Virus / Inmunogenicidad Vacunal / Malaria Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Infant / Male País como asunto: Africa Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Antiprotozoarios / Proteínas Protozoarias / Vacunas contra la Malaria / Vacunas de Partículas Similares a Virus / Inmunogenicidad Vacunal / Malaria Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Infant / Male País como asunto: Africa Idioma: En Año: 2021 Tipo del documento: Article